Nyxoah AI Stock Analysis
Nyxoah (5YI) AI Stock Analysis
Nyxoah
(Frankfurt:5YI)
No summary available
Nyxoah (5YI) vs. iShares MSCI Germany ETF (EWG)
- Market Cap
- EUR 91.66M
- Dividend Yield
- ―
- Average Volume (3M)
- 3,333
- Price to Earnings (P/E)
- -0.4
- Beta (1Y)
- 1.32
- Revenue Growth
- 411.81%
- EPS Growth
- 23.73%
- Country
- Germany
- Employees
- 183
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Instruments & Supplies
Nyxoah Business Overview & Revenue Model
Company Description
Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. It offers Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to...
Nyxoah Earnings Call Summary
The call was predominantly positive, supported by 365% year-over-year global revenue growth, accelerating U.S. sequential growth, expanding surgeon and account adoption, international growth, improved gross margin, positive clinical results, and progress toward a potential CCC indication expansion. The main negative factors were the reduction in full-year 2026 revenue guidance, the sequential decline in cash and financial assets, the continuing operating loss, and the need to manage the commercial ramp. Highlights significantly outweighed lowlights.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
For the full year 2026, Nyxoah expects global net revenue in the range of EUR 33 million-EUR 35 million and gross margin in the range of 60%-62%; the updated revenue guidance is based on U.S. revenues that are more reflective of historical ramps for a new technology, as physicians and centers build experience with Genio. The company’s priorities are to deliver against its updated 2026 revenue guidance, drive utilization in existing U.S. accounts while training new doctors and expanding into new accounts, advance the CCC label expansion opportunity through FDA review of its PMA supplement, and maintain financial discipline while investing behind its highest return and highest growth opportunities.
Nyxoah Risk Analysis
Nyxoah disclosed 77 risk factors in its most recent earnings report. Nyxoah reported the most risks in the "Legal & Regulatory" category.
Latest Risks Added
3 New RisksNyxoah Peers Comparison
Overall Rating
INSP71Outperform
SNN69Neutral
NVCR51Neutral
SENS50Neutral
IRTC48Neutral
STXS46Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| INSP | 71Outperform | $1.80B | 17.84 | 12.49% | ― | -0.19% | 131.98% |
| SNN | 69Neutral | $12.65B | 20.18 | 12.25% | 2.56% | 5.26% | 31.02% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| NVCR | 51Neutral | $1.38B | -11.31 | -35.81% | ― | 12.94% | 33.87% |
| SENS | 50Neutral | $549.45M | -4.45 | -186.15% | ― | 104.83% | -37.15% |
| IRTC | 48Neutral | $2.89B | -75.79 | -22.80% | ― | 21.56% | 27.87% |
| STXS | 46Neutral | $103.21M | -3.70 | -115.83% | ― | 4.83% | 15.55% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| DE:5YI | Nyxoah Sa | 0.76 | -4.44 | -85.46% | |
| NYXH | Nyxoah Sa | 0.90 | -4.41 | -83.05% | |
| IRTC | Irhythm Technologies | 88.68 | -79.82 | -47.37% | |
| INSP | Inspire Medical | 62.11 | -24.67 | -28.43% | |
| SENS | Senseonics Holdings Inc. | 10.42 | 4.24 | 68.61% | |
| STXS | Stereotaxis | 0.90 | -1.34 | -59.82% | |
| NVCR | NovoCure Ltd. | 11.99 | 0.61 | 5.36% | |
| SNN | Smith & Nephew Snats | 31.04 | -1.09 | -3.39% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.